Report Publication Announcement • May 12, 2022
Report Publication Announcement
Open in ViewerOpens in native device viewer
| Informazione Regolamentata n. 20106-38-2022 |
Data/Ora Ricezione 12 Maggio 2022 10:27:23 |
Euronext Star Milan | |
|---|---|---|---|
| Societa' | : | PHARMANUTRA | |
| Identificativo Informazione Regolamentata |
: | 162064 | |
| Nome utilizzatore | : | PHARMANUTRAN04 - Roberto Lacorte | |
| Tipologia | : | REGEM | |
| Data/Ora Ricezione | : | 12 Maggio 2022 10:27:23 | |
| Data/Ora Inizio Diffusione presunta |
: | 12 Maggio 2022 10:27:24 | |
| Oggetto | : | PR - PHN Interim financial report as of 31 March 2022 |
|
| Testo del comunicato |
Vedi allegato.
Pisa, May 12th 2022 - PharmaNutra S.p.A. (MTA; Ticker PHN) announces that the Interim Financial Report as of 31st March 2022, as approved by the Board of Directors of the Company on May 9 th 2022, is available at the Company's registered office, on Pharmanutra S.p.A. website (www.pharmanutra.it, section Investor Relations) and on the authorized storage mechanism "eMarket Storage" available on the website ().
Established and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra is a company established in 2003 that develops unique nutritional supplements and innovative medical devices, taking care of the entire production process, from proprietary raw materials to the finished product. The effectiveness of the products is demonstrated by a wealth of scientific evidence, including 135 publications with over 7,000 subjects involved. The Group distributes and sells in Italy and abroad. In Italy, the sales activity is carried out through a network of over 150 Scientific Sales Representatives at the service of the medical class, also dedicated to the exclusive marketing of PharmaNutra products to pharmacies throughout the country. Sales abroad are guaranteed in over 60 countries through 41 partners selected among the leading pharmaceutical companies. PharmaNutra is a leader in the production of iron-based nutritional supplements under the brand name SiderAL®, for which it boasts key patents for the Sucrosomial® Technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, based on the integrated management of all components: proprietary raw materials, patents, trademarks and clinical evidence.
For further details:
Via Delle Lenze, 216/b - 56122 Pisa Tel. +39 050 7846500 [email protected]
Internal Press Office [email protected]
Via Santa Radegonda, 16 - 20121 Milan Tel. +39 02 83635708
Matteo Russo [email protected] Cristina Tronconi [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.